Real-world safety of fycompa injection under the microscope for epilepsy patients
NCT ID NCT06657378
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study tracks the safety of Fycompa injection in people with epilepsy who have partial-onset seizures (age 4 and older) or primary generalized tonic-clonic seizures (age 12 and older). Researchers will record any side effects and measure drug levels in children aged 4 to 12. No experimental treatment is given; participants receive Fycompa as part of routine care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Fycompa (perampanel) for injection
- What this could lead to
- If the data show Fycompa injection is safe, it could support its use as a treatment option for certain types of seizures.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove effectiveness. Results may be limited by small size and lack of comparison group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARTIAL-ONSET SEIZURES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
1
RECRUITINGTokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New epilepsy drug candidate aims to tame severe seizures
- New seizure drug shows promise in large trial
- New epilepsy drug shows promise for kids in early trial
- Bridge program keeps seizure drug available for eligible patients
- New epilepsy drug shows promise for kids in Long-Term safety trial
- New epilepsy drug XEN1101 tested for long-term seizure control